GLOW
Tier 3 · Reported useThe strongest evidence present is Tier 1, but it applies only to a single component (topical GHK-Cu / copper tripeptide) in controlled human dermatological studies, including a controlled trial after CO2 laser resurfacing and 12-week topical facial-cream studies showing increased collagen synthesis and skin improvements. The GLOW three-peptide blend itself has NO published pharmacological, toxicological, efficacy, or clinical trial data (no RCT). BPC-157 evidence is almost entirely rodent/in-vitro with a single human safety study; TB-500 evidence is cell-culture and animal with no completed human trials. GHK-Cu's robust human data is topical/cosmetic, not injectable. Much of the mechanistic and repair data is in-vitro, animal, or theoretical. Note: a PubMed 'GLOW trial' is an unrelated zolbetuximab cancer study (name collision).
- Half-life
- Not recorded
- Routes
- Subcutaneous injection (most common for the blend) · Topical (GHK-Cu specifically, in cosmetic/dermatological use)
- Goals
- healing · longevity
- Cost / mg
- Not recorded
What's inside
This product is a blend — a stack somebody else already chose. Each ingredient is graded on its own evidence.
The evidence meter beside each ingredient grades that ingredient, studied on its own. It does not carry over to the blend: research on one component is not research on the combination, which is why this page is graded on what has been studied about the mixture itself. Per-vial amounts are not listed here because sellers’ formulations differ — see the overview for what a typical mix is reported to contain.
How it works
GLOW is not a single drug but a community/wellness-market blend that combines three separately studied peptides — GHK-Cu, BPC-157, and TB-500 — marketed for skin quality and recovery. The idea is that each contributes to tissue repair from a different angle: GHK-Cu is a naturally occurring copper-carrying tripeptide that signals skin cells (fibroblasts) to make more collagen, elastin, and other building blocks while calming inflammation; BPC-157 is a fragment of a stomach protein that is proposed to promote new blood-vessel growth and speed healing of soft tissue and gut lining in animals; and TB-500 mimics part of thymosin beta-4 and helps repair cells migrate to injured areas. The claimed benefit of combining them — improved skin and faster recovery than any one alone — is based on theoretical synergy and practitioner reports, not on studies of the blend itself.
Overview
What GLOW Is
GLOW (also called the GLOW blend, GLOW peptide blend, or by its components GHK-Cu + BPC-157 + TB-500) is a community-coined, wellness-market term for a peptide stack, marketed for skin quality and recovery. It is not a regulated product with a fixed formula and is not an FDA-approved single drug.
Formula is not standardized. Most sources define GLOW as GHK-Cu + BPC-157 + TB-500, but sources disagree on ratios and even ingredients. A common vendor formulation uses a 5:1:1 ratio by mass(vendor claim) — roughly 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 (~70 mg total), i.e. ~71.4% GHK-Cu / 14.3% BPC-157 / 14.3% TB-500. Other sources list different totals (e.g. 90 mg) or an entirely different compounded formula (GHK-Cu + glutathione + ascorbic acid). Buyers cannot assume a fixed formula.
The Rationale
The blend combines an extracellular-matrix/collagen-stimulating peptide (GHK-Cu) with two peptides associated with angiogenesis and cell migration (BPC-157 and TB-500). The theory is that combined angiogenic and collagen-stimulating activity creates an optimal repair environment, purportedly resulting in faster recovery than any single component alone. This synergy is theoretical and practitioner-reported — no combination trials exist.
The Components
GHK-Cu
A naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) copper(II) complex present in human plasma, first isolated from human serum in 1973 and shown to prolong survival of normal liver cells at nanomolar concentrations. Plasma levels decline with age (reportedly ~200 ng/mL at age 20 to ~80 ng/mL by age 60, roughly a 60% drop) and rise sharply at sites of tissue injury. It delivers bioavailable copper to metalloenzymes (lysyl oxidase, superoxide dismutase), upregulates TGF-beta signalling, and increases collagen (types I, III, V), elastin, decorin, and glycosaminoglycan synthesis in dermal fibroblasts (collagen stimulation reported at concentrations as low as 0.01 nM). A 2018 review catalogued regulation of over 4,000 human genes. It also suppresses NFκB, promotes DNA repair, activates proteasomal 'cell cleansing,' and stimulates blood-vessel and nerve outgrowth. Preclinical/in-vitro work describes tissue repair in skin, lung, bone, liver, and stomach lining, plus anti-cancer, anti-inflammatory, lung-protective, anti-anxiety, anti-pain, and anti-aggression activities. Secondary and vendor sources report skin effects including tightening loose skin, reversing thinning of aged skin, improving firmness/elasticity/clarity, reducing wrinkles, photodamage, and hyperpigmentation, and increasing hair growth and follicle size(vendor claim). A 2008 Pickart review summarized its roles in wound healing, dermal remodeling, and skin elasticity.
BPC-157
A synthetic 15-amino-acid pentadecapeptide corresponding to a fragment of a protein in human gastric juice. It is proposed to promote healing via VEGFR2 upregulation, nitric-oxide-system modulation, and FAK–paxillin activation, promoting angiogenesis. In tendon fibroblasts it increases FAK and paxillin phosphorylation (boosting migration and survival) and upregulates growth hormone receptor and VEGFR2. It has been studied extensively in rodents for soft-tissue, tendon, ligament, muscle, and GI repair; a cream improved burn/alkali-burn healing in mice and reduced burn-associated gastric ulcers. A 2004 in-vitro study reported it inhibited a melanoma cell line.
TB-500
A synthetic peptide fragment/analog corresponding to the actin-binding domain of thymosin beta-4. It sequesters G-actin to facilitate rapid fibroblast and endothelial cell migration, supporting regeneration of injured tendons, ligaments, and muscle. Research has examined actin sequestration and cytoskeletal regulation in cell culture, migration assays, and animal models of cardiac and dermal tissue. Thymosin beta-4 has been studied for wound healing and anti-inflammatory pathways.
Evidence Snapshot
- The blend itself: No peer-reviewed pharmacological, toxicological, or efficacy studies; no registered human clinical trial or RCT.
- GHK-Cu: Strongest human data is topical/cosmetic — including a controlled trial after CO2 laser resurfacing and 12-week facial-cream studies reporting increased collagen synthesis and improved skin laxity, clarity, wrinkle depth, and density. Animal studies show accelerated wound healing with more granulation tissue, angiogenesis, and better collagen organization. Injectable human data is far more limited.
- BPC-157 & TB-500: Almost entirely preclinical/animal and in-vitro. BPC-157 has one published human safety study; TB-500 has no completed human trials.
- Whether preclinical/animal benefits translate to humans remains unknown. Subjective skin and recovery changes are reported over weeks, not days — typically 4–12 weeks, with peak collagen changes around 8–12 weeks (some sources cite visible firmness at 2–3 weeks).
What the research shows
65 findings extracted from the 18 sources cited below, strongest evidence first within each group. Every one links to the source it came from.
What human studies found
Based on 1 human trial finding, 5 human study findings, 5 in vitro findings and 1 expert opinion finding.
human trialClaudin-18.2 targeting antibody zolbetuximab combined with capecitabine and oxaliplatin improves outcome compared to placebo and chemotherapy as first-line treatment in Claudin-18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas2
human studyGHK's ability to improve tissue repair has been demonstrated for skin, lung connective tissue, boney tissue, liver, and stomach lining1
human studyGHK possesses multiple anti-cancer activities1
human studyGHK possesses anti-inflammatory actions1
human studyGHK provides lung protection and restoration of chronic obstructive pulmonary disease (COPD) fibroblasts1
human studyGHK has anti-anxiety, anti-pain and anti-aggression activities1
in vitroGHK's ability to improve tissue repair has been demonstrated for skin, lung connective tissue, boney tissue, liver, and stomach lining1
in vitroGHK possesses multiple anti-cancer activities1
Show 4 more findingsShow fewer
in vitroGHK possesses anti-inflammatory actions1
in vitroGHK provides lung protection and restoration of chronic obstructive pulmonary disease (COPD) fibroblasts1
in vitroGHK possesses anti-anxiety, anti-pain and anti-aggression activities1
expert opinionWe still really don't know if the benefits seen through pre-clinical and animal trials will actually translate to results with humans16
How it works
Based on 8 human study findings, 6 in vitro findings and 4 theoretical findings.
human studyGHK stimulates blood vessel and nerve outgrowth1
human studyGHK increases collagen, elastin, and glycosaminoglycan synthesis1
human studyGHK supports the function of dermal fibroblasts1
human studyGHK suppresses NFκB molecules thought to accelerate diseases of aging1
human studyGHK supports DNA repair1
human studyGHK activates cell cleansing via the proteasome system1
human studyGHK-Cu is a small, naturally occurring tri-peptide present in human plasma that can be released from tissues in case of injury1
human studyGHK-Cu is able to up- and down-regulate a significant number of human genes1
Show 10 more findingsShow fewer
in vitroGHK suppresses NFκB1
in vitroGHK promotes DNA repair1
in vitroGHK activates cell cleansing via the proteasome system1
in vitroGHK-Cu up- and down-regulates a significant number of human genes1
in vitro31.2% of human genes are stimulated or suppressed by GHK with a change greater than or equal to 50%1
in vitroGHK increases gene expression in 59% of genes, while suppressing it in 41%1
theoreticalGHK stimulates blood vessel and nerve outgrowth1
theoreticalGHK increases collagen, elastin, and glycosaminoglycan synthesis1
theoreticalGHK supports the function of dermal fibroblasts1
theoreticalGHK binds copper(II) ions1
Dosing
Based on 1 expert opinion finding.
expert opinionWithout formal testing, it's hard to recommend the appropriate dosing, route of administration, or frequency of use for injectable peptides16
How the body handles it
Based on 1 human study finding and 2 theoretical findings.
Safety and side effects
Based on 1 human study finding, 8 expert opinion findings and 3 anecdotal findings.
human studyGHK-Cu protects skin cells from UV radiation1
expert opinionPeptide injections, though popular for anti-aging and fitness benefits, often bypass FDA regulation, leaving users exposed to potential risks16
expert opinionThese peptides have not been well-studied or reviewed for safety by the FDA16
expert opinionPeptide injections may cause skin reactions16
expert opinionInjection site effects can include redness, pain, swelling, or skin changes16
expert opinionUnknown drug interactions are a concern with unregulated peptide injections16
expert opinionHeadaches and drowsiness can signal low blood sugar levels from certain FDA-approved peptide injections like Ozempic16
expert opinionThe long-term risks associated with unregulated peptide injections are unclear16
Show 4 more findingsShow fewer
expert opinionInjectable peptides are often made at unregulated compounding pharmacies16
anecdotalSome people who use BPC-157 have reported injection site pain and swelling16
anecdotalSome people have reported fatigue, headaches, and light-headedness after taking unregulated peptide injections16
anecdotalGastrointestinal issues and appetite changes are commonly reported with unapproved injectable peptides16
What people use it for
Based on 6 human study findings, 11 in vitro findings and 2 expert opinion findings.
human studyGHK-Cu tightens loose skin and reverses thinning of aged skin1
human studyGHK-Cu repairs protective skin barrier proteins1
human studyGHK-Cu improves skin firmness, elasticity, and clarity1
human studyGHK-Cu reduces fine lines, depth of wrinkles, and improves structure of aged skin1
human studyGHK-Cu stimulates wound healing1
human studyGHK-Cu increases hair growth and thickness, enlarges hair follicle size1
in vitroGHK-Cu tightens loose skin and reverses thinning of aged skin1
in vitroGHK-Cu repairs protective skin barrier proteins1
Show 11 more findingsShow fewer
in vitroGHK-Cu improves skin firmness, elasticity, and clarity1
in vitroGHK-Cu reduces fine lines, depth of wrinkles, and improves structure of aged skin1
in vitroGHK-Cu smooths rough skin1
in vitroGHK-Cu reduces photodamage, mottled hyperpigmentation, skin spots and lesions1
in vitroGHK-Cu improves overall skin appearance1
in vitroGHK-Cu stimulates wound healing1
in vitroGHK-Cu protects skin cells from UV radiation1
in vitroGHK-Cu reduces inflammation and free radical damage1
in vitroGHK-Cu increases hair growth and thickness, and enlarges hair follicle size1
expert opinionBPC-157 is known for promoting wound healing and injury recovery16
expert opinionCJC-1295 is thought to boost muscle mass16
Points of contention
Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.
Contested
Sources disagree on what GLOW actually contains.
Most sources define GLOW as GHK-Cu + BPC-157 + TB-500 (typically 50/10/10 mg, 70 mg total). However, GLOW Peptide Blend: Mechanism & Research | peptides.fyi lists GHK-Cu 70 mg + BPC-157 10 mg + TB-500 10 mg (90 mg total, different ratio), and Superpower describes GLOW/Klow as a completely different compounded injectable of GHK-Cu + glutathione + ascorbic acid. Buyers cannot assume a fixed formula.
Limited evidence
No studies exist on the GLOW blend itself — evidence is for individual peptides.
Multiple sources state no peer-reviewed pharmacological, toxicological, efficacy, or clinical trials (no RCT) have evaluated the three-peptide combination. Claimed synergy rests on theoretical reasoning and practitioner/anecdotal reports, not combination data.
Limited evidence
Strong GHK-Cu human data is topical/cosmetic; injectable use is largely unstudied.
GHK-Cu's human evidence comes from topical dermatological studies and cell culture; it is FDA-permitted only as a topical cosmetic ingredient. The injectable route used in GLOW protocols has far less published human data. Many GHK-Cu effects (anti-cancer, gene regulation, tissue repair) come from in vitro or theoretical work.
Limited evidence
BPC-157 and TB-500 evidence is almost entirely preclinical/animal.
BPC-157 has been studied almost exclusively in rodents and in vitro, with only one published human safety study and no completed large peer-reviewed human trials. TB-500 lacks completed human clinical trials. Both are on the FDA 503A bulks list as ineligible for compounding.
Contested
BPC-157's angiogenic action raises an unresolved theoretical cancer concern.
A 2023 review warned BPC-157's VEGF/VEGFR2 stimulation could theoretically promote tumor growth in people with existing cancer, but a mouse study found it did not shrink tumors, a 2004 in vitro study found it inhibited a melanoma line, and no clinical trial has evaluated the tumor-promotion question.
Single source
Pharmacokinetic and bioavailability figures come from a single non-authoritative source.
The claimed 65–100% subcutaneous bioavailability and per-dose milligram breakdowns appear only in anecdotal/vendor-style sources (GLOW Blend: GHK-Cu, BPC-157 & TB-500 | Peptide Mind, GLOW Dosage: Complete Protocol, Reconstitution & Frequency Guide), not in peer-reviewed data on the blend.
Other
One cited 'GLOW trial' source is an unrelated cancer drug study.
SPOTlight on GLOW. (PubMed, GLOW trial) concerns zolbetuximab for gastric/gastroesophageal cancer and has no relationship to the GLOW peptide blend — it is a name collision, not evidence for this peptide.
- Tier 1SPOTlight on GLOW.
What you may have heard
The GLOW blend itself has never been tested in a published study — the strong-looking research all belongs to one ingredient studied on its own.
Searching databases like PubMed for 'GLOW' returns several high-quality hits, but they are unrelated projects that happen to share the name — for example a phase 3 cancer-drug trial of zolbetuximab (called the GLOW trial) and various luminescence and 'warm glow' behavioural papers. The only rigorous peer-reviewed paper that actually concerns a GLOW ingredient is a 2018 review of GHK-Cu studied on its own. There are no peer-reviewed pharmacological, toxicological, or efficacy studies of the three-peptide combination, so the apparent depth of evidence is misleading: it reflects one well-studied component, not the blend.
What you may have heard
The strongest human-efficacy evidence for GHK-Cu — a wound-healing trial after CO2 laser resurfacing and a 12-week facial-cream improvement — is described only in vendor write-ups, with no primary trial report cited.
Two of the most concrete human claims for GHK-Cu appear only in commercial product overviews rather than in citable primary studies. The controlled human trial of topical copper tripeptide following CO2 laser resurfacing, in which treated skin reportedly showed improved healing compared with control, is asserted in "GLOW Blend (GHK-Cu, BPC-157 & TB-500): Research Overview, Studies & Mechanism | Peptides.com," which names no underlying trial. The claim that GHK-Cu facial creams applied over 12 weeks improved skin laxity, clarity, wrinkle depth and density comes from "Glow Peptide: Benefits, Dosage & Stack Guide," a vendor guide. Both are commercial sources, and neither reproduces or links the primary trial data behind these human results.
What you may have heard
Assertion that 'one published human safety study' shows BPC-157 tolerability is grounded only in tier-3 vendor sources.
No well-documented completed peer-reviewed human safety trial of BPC-157 is established in the literature; claim 30 cites The GLOW Protocol: Hype, Evidence, and What You're Actually Injecting | Done Dose/Glow Peptide: Does it Work and Where to Buy? – Peptide Insider (vendor pages). The existence of a published human safety study should be verified before stating it as fact.
Single source
The tidy description of BPC-157 as a naturally occurring fragment of a protein in human gastric juice rests largely on the work of a single research group.
BPC-157 is routinely presented as a 15-amino-acid piece of a larger 'body protection compound' identified in human gastric juice. In practice it is a synthetic peptide, and both this origin description and the great majority of the research behind it come predominantly from one group at the University of Zagreb, with only growing but still limited independent replication. The neat 'natural fragment of a gastric protein' story is therefore best read as a research claim that has not been broadly and independently confirmed, rather than a fully settled fact.
Inconsistency
Gene-regulation figures are ambiguous: '>4,000 genes' vs '31.2% of human genes' are not reconcilable.
31.2% of the ~20,000+ human genes would be far more than 4,000. The phrasing conflates 'over 4,000 genes regulated' with '31.2% of human genes,' which may be a garbled rendering of the Pickart data and should be checked against Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.
What you may have heard
Dosed daily as a fixed blend, the TB-500 delivered is lower than the standalone research range for TB-500, and the locked ratio means it can't be raised without pushing the copper peptide beyond its own range.
"GLOW Dosage: Complete Protocol, Reconstitution & Frequency Guide" documents that each blend dose delivers about 0.33 mg TB-500 (alongside ~1.67 mg GHK-Cu and ~0.33 mg BPC-157) on a daily schedule, and that the internal ratio is locked at 50:10:10 and "cannot be tuned per component." "GLOW Blend: GHK-Cu, BPC-157 & TB-500" likewise lists 333 mcg TB-500 taken once daily. By comparison, "Glow Peptide: Benefits, Dosage & Stack Guide" gives separate single-peptide research ranges of GHK-Cu 1–2 mg/day and TB-500 2–2.5 mg twice weekly. The blend's ~0.33 mg/day of TB-500 (roughly 2.3 mg per week) sits below that standalone TB-500 range, and because the ratio is fixed, scaling the blend up to reach it would carry GHK-Cu well above its own cited 1–2 mg/day range.
What you may have heard
The research usually cited for GLOW is actually research on just one of its three ingredients, and the most sweeping claims trace back to reviews written by that ingredient's…
GLOW is often presented as well-researched, but no published study has tested the three-peptide blend itself. The favorable evidence applies to GHK-Cu alone, and even there the controlled human data come from creams applied to the skin, not from injections. The widely repeated claims that GHK-Cu regulates 'over 4,000 genes' and has anti-cancer, anti-aging, and broad tissue-repair benefits trace largely to review articles by Loren Pickart, who first isolated the peptide in 1973 and is affiliated with a company (R&D Skin Biology) selling copper-peptide skincare — a commercial interest worth keeping in mind. On top of that, several scientific papers that surface when searching 'GLOW' are unrelated to this blend (for example, a phase 3 stomach-cancer drug trial of zolbetuximab).
What you may have heard
The GLOW peptide blend has never been tested on its own in any published study; the only strong research covers one of its ingredients (GHK-Cu) applied to the skin.
Searching medical databases for 'GLOW' turns up a lot of results, but almost none are about this peptide blend. The hits include a phase 3 cancer-drug trial (the zolbetuximab GLOW trial) and a string of unrelated papers about bioluminescence and 'glow worms' — none have anything to do with GHK-Cu, BPC-157 or TB-500. The one genuinely relevant high-quality source is a 2018 review of GHK-Cu, and it deals with topical/skin use, not an injected three-peptide mixture; that review is also written by GHK-Cu's long-time commercial proponent. So the apparent depth of scientific literature behind 'GLOW' is misleading: the combination itself has no pharmacology, toxicology, efficacy or human-trial data.
What you may have heard
No study has ever tested the GLOW blend itself, and the peer-reviewed results that seem to back it up are either about a single ingredient or about an unrelated drug.
The three-peptide GLOW blend (GHK-Cu + BPC-157 + TB-500) has no published pharmacological, toxicological, or efficacy studies and no clinical trial. The strongest peer-reviewed source behind it is a 2018 review of GHK-Cu in the International Journal of Molecular Sciences, which covers the copper tripeptide studied on its own — largely in topical and cosmetic skin research — not the injected combination. Separately, medical databases list a phase 3 'GLOW trial,' but that is an unrelated study of the cancer antibody zolbetuximab for stomach cancer, not this peptide blend. In short, the blend's apparent research backing rests on evidence for one component and on similarly named but unrelated studies.
What you may have heard
The GLOW blend has never been tested as a combination in people or animals, and the strongest science behind it applies to just one ingredient used on the skin.
No peer-reviewed pharmacological, toxicological, or efficacy study of the three-peptide GLOW combination has been published; the evidence people cite is drawn entirely from each peptide studied on its own. The most authoritative indexed source is a 2018 review in the International Journal of Molecular Sciences describing GHK-Cu's broad benefits (regulation of thousands of genes, anti-cancer, anti-inflammatory, skin-firming effects), but it was written by Loren Pickart, who first isolated GHK-Cu in 1973 and runs a copper-peptide skincare company — so its sweeping claims carry a commercial interest and are largely a summary of earlier work rather than new blend data. Meanwhile, medical-database searches for 'GLOW' return unrelated studies, such as a phase-3 stomach-cancer antibody trial, not research on this peptide blend. In short, the marketing implies more scientific grounding than exists.
Using it with other compounds
- TB-500Same mechanism
Worth caution
TB-500 (thymosin beta-4 fragment) is already inside GLOW. Adding a separate TB-500 means the same peptide is being administered from two products at once, which is redundant rather than synergistic. Adjust the GLOW dose rather than layering an additional TB-500.
Tier 3Largely anecdotal — commonly discussedShares tissue repair · angiogenesis · anti inflammatory · NF kB modulation · VEGF upregulation
- MatrixylComplementary
May be complementary
Matrixyl is a topical matrikine (Pal-KTTKS) that signals fibroblasts to build type I/III collagen through the MAPK/ERK matrikine route — a different mechanism from GLOW's copper-driven and BPC/TB-driven repair. Used as a topical alongside systemic GLOW, the two converge on collagen and dermal firmness from separate angles, which is a sensible complementary skin-quality pairing.
Tier 4Theoretical — not establishedTiming Topical Matrixyl and systemic GLOW act in different compartments; no timing conflict.
Shares collagen synthesis · dermal matrix · tissue repair
- Palmitoyl Tripeptide-1Same downstream effect
No documented conflict
Palmitoyl Tripeptide-1 is Pal-GHK — essentially a lipidated topical version of the same GHK peptide already delivered (as GHK-Cu) in GLOW. Both drive collagen and matrix synthesis, so a topical Pal-GHK complements GLOW's systemic action, but be aware you are hitting the same GHK matrikine pathway rather than adding a truly independent mechanism.
Tier 4Theoretical — not establishedShares collagen synthesis · dermal matrix · tissue repair · anti inflammatory
- Palmitoyl Tetrapeptide-7Complementary
No documented conflict
Palmitoyl Tetrapeptide-7 is a topical anti-inflammatory peptide that suppresses IL-6/IL-1β and protects the matrix from MMP degradation ('inflammaging'). It complements GLOW's collagen-building and repair actions by calming the cytokine side of skin aging through a distinct route, making it a reasonable topical add-on for skin-quality goals.
Tier 4Theoretical — not establishedShares anti inflammatory · dermal matrix
- PTD-DBMComplementary
No documented conflict
PTD-DBM activates Wnt/β-catenin to drive hair-follicle neogenesis and collagen (including collagen III) production — a different pathway from GLOW's copper/VEGF/actin mechanisms. Since GLOW's GHK-Cu component also has reported hair and collagen effects, the two converge on skin and follicle regeneration from separate angles, a plausible complementary pairing for hair and skin goals.
Tier 4Theoretical — not establishedShares collagen synthesis · dermal matrix · tissue repair
- LL-37Complementary
Worth caution
LL-37 is a cathelicidin that promotes angiogenesis, keratinocyte migration and wound healing via VEGF/EGFR, overlapping with GLOW's repair and angiogenic goals through a distinct innate-immune mechanism. It can complement wound-healing objectives, but note LL-37 is cytotoxic at higher concentrations and has mixed pro-/anti-inflammatory behavior, so dosing restraint is warranted.
Tier 4Theoretical — not establishedShares tissue repair · angiogenesis · anti inflammatory · VEGF upregulation
- BPC-157Same mechanism
Worth caution
BPC-157 is already a component of GLOW. Running a standalone BPC-157 alongside GLOW is redundant double-dosing of the same peptide, so the effect isn't additive — you'd simply be increasing your total BPC-157 exposure. Treat it as one ingredient and titrate the blend instead of stacking a second source.
Tier 3Largely anecdotal — commonly discussedShares tissue repair · angiogenesis · anti inflammatory · mucosal repair · collagen synthesis · NO pathway · VEGF upregulation
- GHK-CuSame mechanism
Worth caution
GHK-Cu is already one of the three peptides inside GLOW. Adding a separate GHK-Cu product on top of GLOW means you are dosing the same ingredient twice, which raises the risk of overshooting rather than adding new benefit. If you want more GHK-Cu, adjust the blend dose rather than stacking a duplicate.
Tier 3Largely anecdotal — commonly discussedShares tissue repair · angiogenesis · anti inflammatory · collagen synthesis · NF kB modulation · VEGF upregulation · dermal matrix
- ElafinComplementary
No documented conflict
Elafin protects tissue by inhibiting destructive neutrophil elastase and proteinase-3 and by dampening NF-κB inflammation — a protease-inhibition mechanism distinct from GLOW's matrix-building action. By preserving elastin and the dermal matrix from enzymatic breakdown while GLOW rebuilds it, the two work on repair from opposite ends (protection vs synthesis).
Tier 4Theoretical — not establishedShares anti inflammatory · mucosal repair · dermal matrix · NF kB modulation · tissue repair
Safety and side effects
Regulatory Status
None of the three peptides are FDA-approved for human use, and GLOW is not an FDA-approved drug product — it is described as a research chemical not for human use.
- GHK-Cu is permitted by the FDA as a cosmetic ingredient for topical use only and is not approved as an injectable drug.
- BPC-157 and TB-500 are on the FDA 503A bulks list as ineligible for compounding. The World Anti-Doping Agency classifies BPC-157 as an S0 'Unapproved Substance.'
Reported / Possible Side Effects
Reported or possible effects of the blend or its injectable route include:
- Injection-site redness, itch, pain, swelling, bruising, edema
- Transient flushing and histamine-type / allergic reactions
- Anecdotal fatigue, headaches, light-headedness, and gastrointestinal/appetite changes
Key Safety Concerns
- Unregulated products & unknown risks. Compounded or unapproved peptide blends carry unknown drug interactions, unclear long-term risks, and are often made at unregulated compounding pharmacies.
- Theoretical cancer concern (BPC-157). A 2023 pharmaceutical review warned that because VEGF/VEGFR2 pathways are active in roughly half of human cancers, BPC-157 could theoretically support tumor growth or metastasis if cancer cells are present. However, no clinical trial has evaluated this, a mouse experiment implanting cancer cells found BPC-157 did not meaningfully shrink tumors, and a 2004 in-vitro study found it inhibited a melanoma line — the question remains unresolved.
- Route matters. GHK-Cu's supportive human safety data is topical; the injectable route used by most GLOW users is largely unstudied in humans.
- Translation unknown. It remains unknown whether benefits seen in preclinical and animal work will translate to humans.
This profile summarizes attributed research claims and is not medical advice.
- Copper load (GHK-Cu). A typical GLOW vial supplies roughly 50 mg of GHK-Cu, a complex that carries bioavailable copper(II), and in this blend it is injected rather than applied to the skin. GHK-Cu's supportive human safety data come almost entirely from topical use; repeated subcutaneous dosing of tens of milligrams of a copper complex has not been studied and raises a plausible concern about systemic copper accumulation. At least one clinical source recommends checking baseline copper status — along with liver function, kidney function, and a complete blood count — before using injectable compounded preparations of this kind.
Reconstitution and handling
Reconstitution (as reported by vendor/anecdotal sources)
No dose has been established for this compound. No regulatory label exists for it, so the figures below are what sources report — not guidance.
These figures come primarily from anecdotal/vendor-style sources, not peer-reviewed data on the blend. They are reported here for completeness, not as guidance.
A common GLOW reconstitution described for a 70 mg vial:
- Add 3 mL bacteriostatic water → concentration ≈ 23.33 mg/mL
- As reported by vendor/anecdotal sources, a 0.10 mL (10-unit) dose delivers ~2.33 mg total blend: ~1.67 mg GHK-Cu, ~0.33 mg BPC-157, ~0.33 mg TB-500 (tier-3 vendor/anecdotal figures, not peer-reviewed)
Administration
- Most GLOW users report subcutaneous injection; GHK-Cu specifically is also used topically (its only FDA-permitted route, as a cosmetic ingredient).
- Subcutaneous injection is claimed to provide 65–100% bioavailability (single non-authoritative source), bypassing digestion for direct bloodstream delivery.
Anecdotal Dosing Protocols
- Cycling example: daily dosing weeks 1–4, 5×/week weeks 5–8, then 2–3×/week maintenance; or a 4 weeks on / 2–4 weeks off cycle.
- Single-peptide ranges cited by tier-3 vendor and secondary sources (for the individual peptides, not the blend, and not peer-reviewed): GHK-Cu 1–2 mg/day, BPC-157 250–500 mcg/day, TB-500 2–2.5 mg twice weekly (tier-3 vendor/secondary figures, not peer-reviewed and not established for the blend).
- Timeline: subjective changes reported over weeks, typically 4–12 weeks, with peak collagen changes around 8–12 weeks (some cite firmness at 2–3 weeks).
Storage
- Lyophilized powder: freeze for long-term storage, or refrigerate up to about four weeks.
- After reconstitution: refrigerate, keep away from light, and use within about a month.
Because there is no standardized formula, exact ratios, totals, and even ingredients vary by vendor — verify what any specific product actually contains.
Sources
Ordered by evidence quality — the strongest first.
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data(opens in a new tab)Tier 1Web · pmc.ncbi.nlm.nih.gov
- SPOTlight on GLOW.(opens in a new tab)Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2023
- Glow in the dark.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2026
- Glow.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
- GLOW: Global Ophthalmic Women.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2024
- We Glow Together: A Dialogue on Luminescent Compounds.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
- Colonoscopic tattooing: ready, steady, glow.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
- DNA Glow.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2020
- Electrostatics affect the glow.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2020
- Neonatal Hypoglycemia: GLOW at the End of the Tunnel?(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2020
- Glow-in-the-dark semiconductor seashells.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2018
- Follow the glow.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2017
- Warm glow.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2011
- Intellectual glow worms.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2009
- Butterfly glow.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 1968
- 4 Dangerous Side Effects of Peptide Injections(opens in a new tab)Tier 3Web · verywellhealth.com
- What doctors want patients to know about injectable peptides(opens in a new tab)Tier 4Web · ama-assn.org
- Warming up cool cooperators.(opens in a new tab)Tier 4PubMed · pubmed.ncbi.nlm.nih.gov · 2023
See something wrong or out of date on this page? Report it.